174 related articles for article (PubMed ID: 7197541)
1. [Pharmacokinetics and biotransformation of the antimycotic drug ciclopiroxolamine in animals and man after topical and systemic administration].
Kellner HM; Arnold C; Christ OE; Eckert HG; Herok J; Hornke I; Rupp W
Arzneimittelforschung; 1981; 31(8A):1337-53. PubMed ID: 7197541
[TBL] [Abstract][Full Text] [Related]
2. [Penetration and antifungal activity of ciclopiroxolamine in hornified tissue (author's transl)].
Dittmar W
Arzneimittelforschung; 1981; 31(8A):1353-9. PubMed ID: 7197542
[TBL] [Abstract][Full Text] [Related]
3. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics and biotransformation following topical use of the local corticoid prednicarbate].
Kellner HM; Eckert HG; Fehlhaber HW; Hornke I; Oekonomopulos R
Z Hautkr; 1986; 61 Suppl 1():18-40. PubMed ID: 3705671
[TBL] [Abstract][Full Text] [Related]
5. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.
Jue SG; Dawson GW; Brogden RN
Drugs; 1985 Apr; 29(4):330-41. PubMed ID: 3158508
[TBL] [Abstract][Full Text] [Related]
6. [Liberation of ciclopiroxolamine from dermatological preparations (author's transl)].
Petri W
Arzneimittelforschung; 1981; 31(8A):1332-7. PubMed ID: 7197540
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man.
Eckert HG; Badian MJ; Gantz D; Kellner HM; Volz M
Arzneimittelforschung; 1984; 34(10B):1435-47. PubMed ID: 6097271
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of labetalol by animals and man.
Martin LE; Hopkins R; Bland R
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
[TBL] [Abstract][Full Text] [Related]
9. A preformulation strategy for the selection of penetration enhancers for a transungual formulation.
Palliyil B; Lebo DB; Patel PR
AAPS PharmSciTech; 2013 Jun; 14(2):682-91. PubMed ID: 23572254
[TBL] [Abstract][Full Text] [Related]
10. Ciclopiroxolamine cream 1%: in vitro and in vivo penetration into the stratum corneum.
Ceschin-Roques CG; Hänel H; Pruja-Bougaret SM; Lagarde I; Vandermander J; Michel G
Skin Pharmacol; 1991; 4(2):95-9. PubMed ID: 1878248
[TBL] [Abstract][Full Text] [Related]
11. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic studies following systemic and topical administration of [14C]bifonazole in man.
Patzschke K; Ritter W; Siefert HM; Weber H; Wegner LA
Arzneimittelforschung; 1983; 33(5):745-50. PubMed ID: 6683553
[TBL] [Abstract][Full Text] [Related]
13. HPLC method for pharmacokinetic studies on ciclopirox olamine in rabbits after intravenous and intravaginal administrations.
Coppi G; Silingardi S
Farmaco; 1992 May; 47(5 Suppl):779-86. PubMed ID: 1524626
[TBL] [Abstract][Full Text] [Related]
14. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy.
Weir SJ; Patton L; Castle K; Rajewski L; Kasper J; Schimmer AD
J Clin Pharm Ther; 2011 Apr; 36(2):128-34. PubMed ID: 21366640
[TBL] [Abstract][Full Text] [Related]
15. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
16. [Studies on the pharmacology and toxicology of ciclopiroxolamine (author's transl)].
Alpermann HG; Schütz E
Arzneimittelforschung; 1981; 31(8A):1328-32. PubMed ID: 7197539
[TBL] [Abstract][Full Text] [Related]
17. [Clinical results with the antimycotic agent ciclopiroxolamine (author's transl)].
Adam W; Peil HG; Savopoulos C; Vanderbeke O
Arzneimittelforschung; 1981; 31(8A):1360-5. PubMed ID: 7028047
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Ciclopirox Olamine after Buccal Administration in Rabbits.
Lukášová I; Muselík J; Vetchý D; Gajdziok J; Gajdošová M; Juřica J; Knotek Z; Hauptman K; Jekl V
Curr Drug Deliv; 2017; 14(1):99-108. PubMed ID: 27138296
[TBL] [Abstract][Full Text] [Related]
20. Absorption and disposition of 14C-labelled Kathon biocide, a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one, following intravenous or dermal administration to male Sprague-Dawley rats.
deBethizy JD; Longacre SL; Steigerwalt RB; Deckert FW; Moss JN; Hayes AW; Smith JM; Scribner HE
Food Chem Toxicol; 1986 Jan; 24(1):43-9. PubMed ID: 3949268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
